Limited Cutaneous Systemic Sclerosis

Watchlist

(log in to enable)

Retrieved

2022-04-26

Source

Gard

Trials

—

Genes

HLA-DRB1, KIAA0319L, CAV1, IRF5, CCN2, CCR6, SOX10, IL6, FAS, CD22, TAP1, MITF, MRC1, NOS1, NOS2, PAH, CCL4, CCL18, SOX5, ACVRL1, SSB, TAP2, TGFB1, TIMP1, TNF, HSP90B2P, TTR, VIM, RABEP1, SS18L1

HLA-DRB1, KIAA0319L, CAV1, IRF5, CCN2, CCR6, SOX10, IL6, FAS, CD22, TAP1, MITF, MRC1, NOS1, NOS2, PAH, CCL4, CCL18, SOX5, ACVRL1, SSB, TAP2, TGFB1, TIMP1, TNF, HSP90B2P, TTR, VIM, RABEP1, SS18L1, IL21R, RXFP1, JAK2, CXCL10, CD86, GRB10, CHI3L1, CCR1, C1QC, C1QB, CTSV, GADD45A, EGFR, FCGR3A, FCGR3B, FYN, HLA-B, IL13, CCND1, HMGB1, HOXC8, DNAJB1, IRF8, IFI16, IL2, ACTB, CXCL8, IL10, ACR

Drugs

(1'R,6'R)-3-(benzylamine)-6-hydroxy-3'-methyl-4-pentyl-6'-(prop-1-en-2-yl)-[1,1'-bi(cyclohexane)]-2',3,6-triene-2,5-dione, 2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione, 2-[4-Methoxy-3-(2-m-tolyl-ethoxy)-benzoylamino]-indan-2-carboxylic acid, Bosentan ( STAYVEER, TRACLEER ), Caprine hyperimmune serum against HIV lysate, Halofuginone hydrobromide, Human engineered monoclonal antibody specific for transforming growth factor ß1, Lenabasum, Nintedanib ( OFEV ), Nitroglycerin, Paquinimod, Peptide 144 TGF-beta1-inhibitor (TSLDASIIWAMMQN), Pomalidomide ( IMNOVID (previously POMALIDOMIDE CELGENE), POMALYST ), Riociguat ( ADEMPAS ), Terguride, Tocilizumab ( ACTEMRA, ROACTEMRA ), Treprostinil diethanolamine (oral use) ( ORENITRAM ), Type I native bovine skin collagen, autologous adipose tissue-derived stromal vascular fraction cells, romilkimab, ziritaxestat

Interested in hearing about new therapies?

Limited cutaneous systemic sclerosis is a subtype of systemic sclerosis characterized by the association of Raynaud's phenomenon and skin fibrosis on the hands, face, feet and forearms. The exact cause of limited cutaneous systemic sclerosis is unknown, but likely originates from an autoimmune reaction which leads to overproduction of collagen. In some cases, the condition is associated with exposure to certain chemicals. Management is aimed at treating the symptoms present in each affected individual.